Last updated: February 13, 2026
What is NDC 00173-0781?
NDC 00173-0781 corresponds to Invega Sustenna (paliperidone palmitate), an injectable atypical antipsychotic approved for schizophrenia treatment in adult patients. It is a long-acting version administered via monthly intramuscular injections.
Market Overview
Market Size and Key Drivers
-
Global schizophrenia market size was valued at $13 billion in 2022, with a forecasted compound annual growth rate (CAGR) of approximately 4.8% through 2030. Growth drivers include increasing prevalence rates, expanded indications, and demand for long-acting injectables (LAIs).
-
U.S. market share dominates due to high prevalence of schizophrenia (approximately 1 million adults as per CDC [1]) and a preference for LAIs. Invega Sustenna holds an estimated 40-45% share among LAI antipsychotics.
-
Competitive landscape comprises drugs like Abilify Maintena (aripiprazole), Risperdal Consta (risperidone), and new entrants such as drug-device combination products. The introduction of biosimilars or generics could influence market dynamics but remains limited for long-acting antipsychotics due to patent protections.
Patent Status and Exclusivity
-
The original patent protection for Invega Sustenna expired in 2026, but patent disputes and additional exclusivities (e.g., data protection) can extend market exclusivity until around 2031.
-
Regulatory exclusivities: Orphan drug, pediatric, and formulation-specific patents may prolong market exclusiveness.
Pricing Dynamics
-
The average wholesale price (AWP) for Invega Sustenna in 2023 is approximately $2,200 per monthly dose, but actual payer prices are typically 20-30% lower due to discounts and negotiations.
-
The average out-of-pocket cost for patients varies by insurance coverage but generally ranges from $50 to $150 per month.
-
Price trends over the past five years show stability with minor fluctuations, driven by negotiated discounts and procurement policies.
Price Projections
Short-term (Next 1-2 Years)
-
Pricing stability: Given patent protections and high brand loyalty, prices are expected to remain stable at around $2,200 per injection.
-
Market growth impact: As demand for LAIs continues to increase due to adherence advantages, sales volume growth could slightly elevate revenue, but unit prices are unlikely to change significantly.
Medium-term (Next 3-5 Years)
-
Patent expiries and biosimilar entry: Potential generic or biosimilar competitors could emerge by 2026-2028, exerting downward pressure on prices by approximately 15-25%.
-
Price decline estimates: Generic versions may price between 20-40% lower than branded formulations, with wholesale prices dropping to approximately $1,600-$1,800 per dose.
Long-term (Beyond 5 Years)
-
Market saturation and regulatory events: If biosimilar competition intensifies, branded price points could decline further, possibly stabilizing around $1,400-$1,600 per dose.
-
Premium for formulation and service: Manufacturers leveraging improved formulations or delivery devices might sustain higher prices within niche segments.
Competitive Forecasting and Market Potential
| Year |
Estimated Market Size (USD billions) |
Key Drivers |
Pricing Trend |
| 2023 |
1.8 |
Rising LAI adoption; high unmet need |
Stable at ~$2,200 per dose |
| 2024-2025 |
2.0 |
Continued adoption; existing patents |
Slight decline expected (~5%) |
| 2026-2028 |
2.2-2.4 |
Introduction of biosimilars; patent expiry |
Price decline (~20%) |
| 2029+ |
2.5-3.0 |
Market saturation; new therapies |
Stabilize at lower prices |
Regulatory and Policy Impacts
-
Pricing controls in markets such as the U.S. and Europe might influence the product’s price structure over the next decade.
-
Medicaid and Medicare policies may further pressure net prices through preferred formulary inclusion and rebates.
-
Value-based pricing models gaining traction could impact reimbursement based on patient outcomes, especially with reduced hospitalizations and improved adherence from LAIs.
Key Takeaways
-
NDC 00173-0781 (Invega Sustenna) maintains a dominant position in the LAI antipsychotic market.
-
Original patent protections limit generic competition until approximately 2026-2028, with prices around $2,200 per dose.
-
Entry of biosimilars is expected to decrease prices by 15-25% over the next 3-5 years.
-
Long-term prices may stabilize around $1,400-$1,600 per dose, contingent on competitive pressures and regulatory changes.
-
Market growth relies on increased mental health awareness, adherence benefits of LAIs, and healthcare system policies.
FAQs
1. When will generic versions of Invega Sustenna be available?
Patent expiry is projected around 2026, with biosimilar development potentially leading to availability between 2026 and 2028.
2. How might biosimilar entry affect the market?
Biosimilars would likely drive prices 20-40% lower, reducing overall revenue for the branded product but expanding treatment access.
3. What are the main factors influencing price stability?
Patents, formulary coverage, payer negotiations, and the competitive landscape.
4. How does pricing vary across regions?
US prices are generally higher; in Europe and other markets, prices are often negotiated down through health authorities and tend to be lower.
5. What are the implications for R&D investments?
Patent expiries and market saturation suggest increased interest in next-generation formulations or combination therapies before significant biosimilar competition arrives.
References
[1] CDC – Schizophrenia Prevalence Data, 2022.
